HighTower Advisors’s Viridian Therapeutics VRDN Stock Holding History

HighTower Advisors’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-814	Closed	-$10K	–	2548
2019 Q3	$10K	Sell	814 -101	-11%	-$2.23K	﹤0.01%	2306
2019 Q2	$27K	Hold	915	–	–	﹤0.01%	2248
2019 Q1	$39K	Hold	915	–	–	﹤0.01%	2136
2018 Q4	$42K	Sell	915 -330	-27%	-$19.1K	﹤0.01%	2042
2018 Q3	$103K	Sell	1,245 -51	-4%	-$4.81K	﹤0.01%	2048
2018 Q2	$124K	Hold	1,296	–	–	﹤0.01%	1974
2018 Q1	$137K	Sell	1,296 -33	-2%	-$3.58K	﹤0.01%	1936
2017 Q4	$208K	Sell	1,329 -73	-5%	-$9.3K	﹤0.01%	1900
2017 Q3	$194K	Buy	1,402 +666	+90%	+$112K	﹤0.01%	1922
2017 Q2	$143K	Sell	736 -1,788	-71%	-$302K	﹤0.01%	1897
2017 Q1	$471K	Buy	2,524 +431	+21%	+$74.3K	﹤0.01%	1355
2016 Q4	$158K	Hold	2,093	–	–	﹤0.01%	1724
2016 Q3	$235K	Buy	2,093 +264	+14%	+$29.4K	﹤0.01%	1562
2016 Q2	$174K	Hold	1,829	–	–	﹤0.01%	1525
2016 Q1	$210K	Buy	1,829 +311	+20%	+$39.7K	﹤0.01%	1788
2015 Q4	$256K	Hold	1,518	–	–	﹤0.01%	1643
2015 Q3	$317K	Buy	+1,518	New	+$533K	﹤0.01%	1434

Other funds holding VRDN

AVA

Atlas Venture Advisors Boston, Massachusetts $122M AUM 26.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

HighTower Advisors's VRDN Position: Q4 2019 in Review

HighTower Advisors sold out of Viridian Therapeutics (VRDN) in Q4 2019, closing a stake of 814 shares — an estimated $10K sold.

HighTower Advisors first reported a position in VRDN in Q3 2015 and held it in 17 quarters. The position peaked at $471K in Q1 2017. 23 funds tracked by Wall St. Rank hold VRDN as of Q4 2019.

HighTower Advisors reported no remaining Viridian Therapeutics position as of Q4 2019 after selling out during the quarter.
HighTower Advisors sold 814 Viridian Therapeutics shares in Q4 2019, an estimated $10K.
HighTower Advisors first reported a position in Viridian Therapeutics in Q3 2015 and held it in 17 quarters.
HighTower Advisors's Viridian Therapeutics position peaked at $471K in Q1 2017.
23 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q4 2019.

Based on HighTower Advisors's 13F filing for Q4 2019, filed 14 Feb 2020.